Bluejay Diagnostics, Inc. (BJDX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bluejay Diagnostics, Inc. on August 13, 2026. The filing serves as a Regulation FD disclosure referencing a press release issued on the same date. The press release provides a business and financial update for the fiscal second quarter ended June 30, 2026, following the filing of the corresponding Form 10-Q on August 12, 2026.
Key Financial Metrics
The provided text is a cover page and index for the 8-K filing and does not contain specific financial data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this document. Investors must refer to the referenced Form 10-Q or the attached press release (Exhibit 99.1) for these figures.
Material Changes
The filing text does not detail specific material changes in financial performance or operations compared to prior periods. It solely indicates that an update regarding the second quarter of 2026 was issued.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, or contingencies are not detailed in the text of this 8-K. The document notes that the information in Item 7.01 and Exhibit 99.1 is furnished and not "filed" for purposes of the Securities Exchange Act of 1934, nor is it incorporated by reference unless specifically identified.
Investor Verification Checklist
- Verify the specific financial results for the quarter ended June 30, 2026, by reviewing the Form 10-Q filed on August 12, 2026.
- Review Exhibit 99.1 (Press Release dated August 13, 2026) for management's commentary and business updates.
- Confirm the company's status as an emerging growth company, as indicated by the checkmark in the filing.
- Note that the information in this 8-K is not incorporated by reference into other filings unless explicitly stated.